Hemocompatibility and Biophysical Interface of Left Ventricular Assist Devices and Total Artificial Hearts

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2023 Oct 27

PMID 37890145

Authors

Angelo Nascimbene

David Bark

David M Smadja

Affiliations

Soon will be listed here.

Abstract

Over the past 2 decades, there has been a significant increase in the utilization of long-term mechanical circulatory support (MCS) for the treatment of cardiac failure. Left ventricular assist devices (LVADs) and total artificial hearts (TAHs) have been developed in parallel to serve as bridge-to-transplant and destination therapy solutions. Despite the distinct hemodynamic characteristics introduced by LVADs and TAHs, a comparative evaluation of these devices regarding potential complications in supported patients, has not been undertaken. Such a study could provide valuable insights into the complications associated with these devices. Although MCS has shown substantial clinical benefits, significant complications related to hemocompatibility persist, including thrombosis, recurrent bleeding, and cerebrovascular accidents. This review focuses on the current understanding of hemostasis, specifically thrombotic and bleeding complications, and explores the influence of different shear stress regimens in long-term MCS. Furthermore, the role of endothelial cells in protecting against hemocompatibility-related complications of MCS is discussed. We also compared the diverse mechanisms contributing to the occurrence of hemocompatibility-related complications in currently used LVADs and TAHs. By applying the existing knowledge, we present, for the first time, a comprehensive comparison between long-term MCS options.

References

Cooper B, Roszelle B, Long T, Deutsch S, Manning K . The influence of operational protocol on the fluid dynamics in the 12 cc Penn state pulsatile pediatric ventricular assist device: the effect of end-diastolic delay. Artif Organs. 2010; 34(4):E122-33. PMC: 2861303. DOI: 10.1111/j.1525-1594.2009.00852.x. View

Seese L, Hickey G, Keebler M, Thoma F, Kilic A . Limited Efficacy of Thrombolytics for Pump Thrombosis in Durable Left Ventricular Assist Devices. Ann Thorac Surg. 2020; 110(6):2047-2054. DOI: 10.1016/j.athoracsur.2020.03.061. View

Grosman-Rimon L, Hui S, Freedman D, Elbaz-Greener G, Cherney D, Rao V . Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device Implantation. Cardiorenal Med. 2019; 9(2):108-116. DOI: 10.1159/000494090. View

Netuka I, Pya Y, Poitier B, Ivak P, Konarik M, Perles J . First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart. ASAIO J. 2021; 67(10):1100-1108. PMC: 8478302. DOI: 10.1097/MAT.0000000000001485. View

Richez U, De Castilla H, Guerin C, Gendron N, Luraghi G, Grimme M . Hemocompatibility and safety of the Carmat Total Artifical Heart hybrid membrane. Heliyon. 2019; 5(12):e02914. PMC: 6906674. DOI: 10.1016/j.heliyon.2019.e02914. View

Wu W, Yang F, Wu J, Aubry N, Massoudi M, Antaki J . High fidelity computational simulation of thrombus formation in Thoratec HeartMate II continuous flow ventricular assist device. Sci Rep. 2016; 6:38025. PMC: 5131309. DOI: 10.1038/srep38025. View

Schaub R, Kameneva M, Borovetz H, Wagner W . Assessing acute platelet adhesion on opaque metallic and polymeric biomaterials with fiber optic microscopy. J Biomed Mater Res. 1999; 49(4):460-8. DOI: 10.1002/(sici)1097-4636(20000315)49:4<460::aid-jbm4>3.0.co;2-3. View

Woolley J, Teuteberg J, Bermudez C, Bhama J, Lockard K, Kormos R . Temporal leukocyte numbers and granulocyte activation in pulsatile and rotary ventricular assist device patients. Artif Organs. 2014; 38(6):447-55. PMC: 4010558. DOI: 10.1111/aor.12200. View

Goda M, Jacobs S, Rega F, Peerlinck K, Jacquemin M, Droogne W . Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. J Heart Lung Transplant. 2013; 32(5):539-45. DOI: 10.1016/j.healun.2013.02.006. View

10.

Kaya E, Kocabas U, Simsek E, Nalbantgil S, Kahraman U, Engin C . Effects of Continuous-Flow Left Ventricular Assist Device Therapy on Peripheral Vascular Function. ASAIO J. 2022; 68(2):214-219. DOI: 10.1097/MAT.0000000000001447. View

11.

Nascimbene A, Hilton T, Konkle B, Moake J, Frazier O, Dong J . von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support. J Heart Lung Transplant. 2017; 36(4):477-479. PMC: 5944844. DOI: 10.1016/j.healun.2017.01.010. View

12.

Park S, Milano C, Tatooles A, Rogers J, Adamson R, Steidley D . Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012; 5(2):241-8. DOI: 10.1161/CIRCHEARTFAILURE.111.963991. View

13.

Panteleev M, Korin N, Reesink K, Bark D, Cosemans J, Gardiner E . Wall shear rates in human and mouse arteries: Standardization of hemodynamics for in vitro blood flow assays: Communication from the ISTH SSC subcommittee on biorheology. J Thromb Haemost. 2021; 19(2):588-595. DOI: 10.1111/jth.15174. View

14.

Sun H, Zeng D, Li R, Pang R, Yang H, Hu Y . Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012; 60(6):1407-14. DOI: 10.1161/HYPERTENSIONAHA.112.197301. View

15.

Slaughter M, Rogers J, Milano C, Russell S, Conte J, Feldman D . Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23):2241-51. DOI: 10.1056/NEJMoa0909938. View

16.

Wieselthaler G, O Driscoll G, Jansz P, Khaghani A, Strueber M . Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant. 2010; 29(11):1218-25. DOI: 10.1016/j.healun.2010.05.016. View

17.

Chatterjee A, Feldmann C, Hanke J, Ricklefs M, Shrestha M, Dogan G . The momentum of HeartMate 3: a novel active magnetically levitated centrifugal left ventricular assist device (LVAD). J Thorac Dis. 2018; 10(Suppl 15):S1790-S1793. PMC: 6035956. DOI: 10.21037/jtd.2017.10.124. View

18.

Asleh R, Albitar H, Schettle S, Kushwaha S, Pereira N, Behfar A . Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding. J Heart Lung Transplant. 2020; 39(5):492-495. DOI: 10.1016/j.healun.2020.02.012. View

19.

Arora D, Behr M, Pasquali M . Hemolysis estimation in a centrifugal blood pump using a tensor-based measure. Artif Organs. 2006; 30(7):539-47. DOI: 10.1111/j.1525-1594.2006.00256.x. View

20.

Guerin C, Guyonnet L, Goudot G, Revets D, Konstantinou M, Chipont A . Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells. Stem Cell Rev Rep. 2020; 17(2):639-651. PMC: 7670993. DOI: 10.1007/s12015-020-10062-1. View